share_log

EFFECT: Others

EFFECT: Others

EFFECT:其他
美股SEC公告 ·  09/10 18:03

Moomoo AI 已提取核心信息

ZyVersa Therapeutics, Inc., a biopharmaceutical company, has achieved a significant milestone with the Notice of Effectiveness from the United States Securities and Exchange Commission (SEC) as of 5:00 P.M. on September 9, 2024. The notice pertains to Form S-3, which is commonly used by companies to register securities for potential future offerings. This development indicates that ZyVersa Therapeutics has met the necessary regulatory requirements to move forward with the registration of its securities, as documented under file number 333-281913. The effectiveness of the form is a crucial step for the company, potentially paving the way for future capital raising activities through the sale of registered securities.
ZyVersa Therapeutics, Inc., a biopharmaceutical company, has achieved a significant milestone with the Notice of Effectiveness from the United States Securities and Exchange Commission (SEC) as of 5:00 P.M. on September 9, 2024. The notice pertains to Form S-3, which is commonly used by companies to register securities for potential future offerings. This development indicates that ZyVersa Therapeutics has met the necessary regulatory requirements to move forward with the registration of its securities, as documented under file number 333-281913. The effectiveness of the form is a crucial step for the company, potentially paving the way for future capital raising activities through the sale of registered securities.
ZyVersa Therapeutics是一家生物制药公司,通过美国证券交易委员会(SEC)于2024年9月9日下午5:00获得了重要的里程碑——有效通知。该通知涉及S-3表格,这是公司通常用来注册潜在未来发行的证券。这一进展表明ZyVersa Therapeutics已满足继续注册其证券的必要监管要求,文件号为333-281913。该表单的有效性对公司而言是关键步骤,可能为未来通过出售注册证券进行资本筹集活动铺平道路。
ZyVersa Therapeutics是一家生物制药公司,通过美国证券交易委员会(SEC)于2024年9月9日下午5:00获得了重要的里程碑——有效通知。该通知涉及S-3表格,这是公司通常用来注册潜在未来发行的证券。这一进展表明ZyVersa Therapeutics已满足继续注册其证券的必要监管要求,文件号为333-281913。该表单的有效性对公司而言是关键步骤,可能为未来通过出售注册证券进行资本筹集活动铺平道路。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息